RT Journal Article
SR Electronic
T1 COVID-19 illness, SARS-CoV2 infection, and subsequent suicidal ideation in the French nationwide population-based EpiCov cohort : a propensity score analysis of more than 50,000 individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.02.22278311
DO 10.1101/2022.08.02.22278311
A1 Camille Davisse-Paturet
A1 Massimiliano Orri
A1 Stéphane Legleye
A1 Aline-Marie Florence
A1 Jean-Baptiste Hazo
A1 Josiane Warszawski
A1 Bruno Falissard
A1 Marie-Claude Geoffroy
A1 Maria Melchior
A1 Alexandra Rouquette
A1 the EPICOV study group
YR 2022
UL http://medrxiv.org/content/early/2022/08/03/2022.08.02.22278311.abstract
AB Symptomatic COVID-19 appears to be associated with suicidal ideation but longitudinal evidence is still scarce. SARS-CoV2-induced neurological damages might underline this association, but findings are inconsistent. We therefore investigated the association between COVID-19 disease and subsequent suicidal ideation in the general population, using both self-reported symptoms and serology as well as inverse probability weighting to draw as near as possible to the direct association.Using data from the nationwide French EpiCov cohort, COVID-19 disease was assessed through 1) COVID-19 illness (self-reported symptoms of sudden loss of taste/smell or fever alongside cough, shortness of breath or chest oppression, between February and November 2020), and 2) SARS-CoV2 infection (Spike protein ELISA test screening in dried-blood-spot samples). Suicidal ideation was self-reported between December 2020 and July 2021. Inverse probability weighting with propensity scores was used as an adjustment strategy, leading to balanced sociodemographic and health-related factors between the exposed and non-exposed groups of both COVID-19 disease measures. Then, modified Poisson regression models were used to investigate the association of COVID-19 illness and SARS-CoV2 infection with subsequent suicidal ideation.Among 52,050 participants from the EpiCov cohort, 1.68% [1.54% - 1.82%] reported suicidal ideation in the first half of 2021, 9.57% [9.24% – 9.90%] had a SARS-CoV2 infection in 2020 and 13.23% [12.86% – 13.61%] reported COVID-19 symptoms in 2020. COVID-19 illness in 2020 was associated with higher risks of subsequent suicidal ideation in the first half of 2021 (Relative Riskipw [CI95%]= 1.43 [1.20 – 1.69]) while SARS-CoV2 infection in 2020 was not (RRipw = 0.88 [0.69 – 1.12]).If COVID-19 illness was associated with subsequent suicidal ideation, the exact role of SARS-CoV2 infection with respect to suicide risk has yet to be clarified. Psychological support should be offered to persons recovering from symptomatic COVID-19 in order to minimize suicidal ideation risk. Moreover, if such psychological support is to be implemented, serology status alone does not seem a relevant criterion to define persons who suffered from COVID-19 to prioritize.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present work was supported by a French National Observatory of Suicide research grant attributed to AR (grant number R21094LL). The EpiCov study was supported by research grants from Inserm (Institut National de la Sante et de la Recherche Medicale), the French Ministry for Research and its department of research, studies, evaluation and statistics (Direction de la Recherche, des Etudes, Evaluation et Statistiques, Drees), the French Ministry for Health, and the Region Ile de France. Dr.Bajos has received funding from the European Research Council (ERC) under the Horizon 2020 research and innovation program of the European Union (grant agreement number 856478). This project has also received funding from the Horizon 2020 research and innovation program of the European Union under grant agreement number 101016167, ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The EpiCov study received approval from an ethics committee (Comite de Protection des Personnes Sud Mediterranee III 2020- A01191-38) and from the French National Data Protection Agency (Commission Nationale Informatique et Libertes, CNIL, MLD/MFI/AR205138).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymous aggregated data for the baseline wave are available online. The EpiCov dataset is available for research purpose concerning baseline wave, and will be available by March 2022 concerning the second follow-up wave for research purpose on CASD (https://www.casd.eu/), after submission to approval of French Ethics and Regulatory Committee procedure (Comite du Secret Statistique, CESREES and CNIL). Access to anonymized individual data underlying the findings may be available before the planned period, on request to the corresponding author, to be submitted to approval of ethics and reglementary Committee for researchers who meet the criteria for access to data.